Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

MYLAN NV (MYL)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2018 05/21/2018 05/22/2018 05/23/2018 05/24/2018 Date
39.66(c) 39.55(c) 39.21(c) 39.63(c) 39.29 Last
4 590 536 2 594 543 2 819 859 3 892 481 1 687 568 Volume
-1.05% -0.28% -0.86% +1.07% -0.86% Change
More quotes
Financials (USD)
Sales 2018 12 319 M
EBIT 2018 3 794 M
Net income 2018 1 351 M
Debt 2018 13 179 M
Yield 2018 -
Sales 2019 12 943 M
EBIT 2019 3 950 M
Net income 2019 1 630 M
Debt 2019 10 654 M
Yield 2019 -
P/E ratio 2018 13,00
P/E ratio 2019 10,72
EV / Sales2018 2,73x
EV / Sales2019 2,40x
Capitalization 20 426 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom. 
Sector
Pharmaceuticals
Calendar
06/29Shareholder meeting
More about the company
Surperformance© ratings of Mylan NV
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN NV
01:26pMYLAN NV : Free Daily Technical Summary Reports on Mylan and Three Other Generic..
AC
05/18GSK bets on lift from new lung drugs ahead of Advair's last gasp
RE
05/16Evolus investors frown as FDA declines to approve Botox rival
RE
05/14MYLAN : and West Virginia University Join Forces to Inspire West Virginia Youth ..
PR
05/10In Europe, Mylan's rivals try to plug EpiPen shortages
RE
05/09MYLAN : May Be Gem in Rough Generic Sector
DJ
05/09MYLAN : Statement on Supply of EpiPen® (epinephrine injection, USP) Auto-Injecto..
PU
05/09MYLAN : Reports First Quarter 2018 Results and Reaffirms 2018 Guidance
PR
05/02MYLAN : to Release First Quarter 2018 Financial Results on May 9, 2018
PR
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
More news
Sector news : Pharmaceuticals - NEC
08:17aNOVARTIS : Biosimilar Zessly Gets European Commission Nod
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07:30aGLAXOSMITHKLINE : GSK May Look at Merger Options for Indian Unit -The Economic T..
DJ
01:16aJ&J hit with $21.7 million verdict in another talc asbestos cancer case
RE
12:28aEXCLUSIVE - U.S. WANTS CHINA TO APPR : sources
RE
More sector news : Pharmaceuticals - NEC
Latest Tweets
01:12pMylan given $53.00 PT by JPMorgan Chase & Co.. buy rating.  
01:01p$SPY $QQQ $AAPL $ALK $BMWYY $CMCSA $DB $DDAIF $DIS $LOW $MCD $MYL $NFLX $PFE .. 
09:00aEpiPen shortage heaps pressure on Pfizer
1
12:30a$GLRE $AGO $URI $GM $BHF $AER $MYL $GRBK $VOYA $PRGO $MU $CNX $AABA $AAPL $ES.. 
05/23$MYL New Form 8-K for Mylan NV From our Stock News Alerts App 
More tweets
Qtime:136
News from SeekingAlpha
07:01aWALL STREET BREAKFAST : U.S. Revs Up Auto Import Probe 
03:00aEpiPen shortage heaps pressure on Pfizer 
05/23MINING FOR ASCO 2018'S GOLD, PART 1 : Early Breast Cancer Has Some Sheen 
05/23Tracking David Einhorn's Portfolio - Q1 2018 Update 
05/18Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update 
Chart MYLAN NV
Duration : Period :
Mylan NV Technical Analysis Chart | MYL | NL0011031208 | 4-Traders
Technical analysis trends MYLAN NV
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 49,7 $
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Director
Rajiv Malik President & Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN NV-6.33%20 426
JOHNSON & JOHNSON-11.45%331 111
PFIZER-1.16%210 409
NOVARTIS-6.94%200 805
ROCHE HOLDING LTD.-9.17%191 486
MERCK AND COMPANY3.87%159 185